Mark A. Goldsmith Salary and Compensation - Revolution Medicines, Inc. CEO Pay 2025

In fiscal year 2025, Mark A. Goldsmith, M.D., Ph.D. of Revolution Medicines, Inc. (RVMD), received total compensation of $14.7 million.

Mark A. Goldsmith's compensation breakdown includes: base salary of $813K, stock awards valued at $4.0 million, option awards of $9.0 million, non-equity incentive compensation of $890K, and other compensation of $7K.

Compared to fiscal year 2024, Mark A. Goldsmith's total compensation increased 46% from $10.1 million to $14.7 million.

Revolution Medicines, Inc. (RVMD) Executive Pay 2025

Revolution Medicines, Inc.'s top 5 named executive officers received combined total compensation of $32.8 million in fiscal year 2025.

The named executive officers disclosed in Revolution Medicines, Inc.'s 2025 proxy statement are:Mark A. Goldsmith (M.D., Ph.D.) with total compensation of $14.7 million, Stephen M. Kelsey (M.D., FRCP, FRCPath) with total compensation of $6.0 million, Margaret Horn (J.D.) with total compensation of $4.8 million, Jeffrey Cislini (General Counsel and Secretary) with total compensation of $3.7 million, and Jack Anders (Chief Financial Officer) with total compensation of $3.6 million.